Presenting
Destiny Pharma
Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.
Destiny Pharmas vision is of an expanding range of new antimicrobial drug products which operate within existing antibiotic markets but due to their unique features, open significant, new markets that are closed to traditional antibiotics due to the existence or threat of antibiotic resistance.
The proprietary, new antimicrobial drug platform at Destiny Pharma, the XF Drug Series, act via an ultra-rapid action which kill bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance response.
Diurnal
Founded in 2004, Diurnal is a UK-based, globally-focused specialty pharma company developing high quality products for the life-long treatment of chronic endocrine conditions.
They are committed to addressing major unmet clinical and patient needs in hormone replacement, initially by developing and marketing products for the rare orphan diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI).
Diurnals expertise and innovative research activities focus on circadian-based endocrinology (mimicking the bodys natural hormone levels), which has yielded novel product candidates being trialled in patients prior to the submission of a marketing authorisation application.
India Capital Growth Fund
The India Capital Growth Fund (ICGF) is a closed ended Investment Company, listed on the main board of the London Stock Exchange. It follows a bottom-up long-term investment approach focused on Indias small and midcap market with a concentrated portfolio of around 30 holdings. ICGF is managed by Ocean Dial, a single country focused asset management company investing directly into India.
Warehouse REIT
The investment objective is to provide shareholders with an attractive level of income together with the potential for income and capital growth by investing in a diversified portfolio of UK commercial property warehouse assets
